千金藥業(600479.SH):擬推1255.52萬股的2021年限制性股票激勵計劃
格隆匯11月24日丨千金藥業(600479.SH)公佈2021年限制性股票激勵計劃(草案),該計劃擬授予激勵對象1255.52萬股限制性股票,約佔公司目前總股本41,850.71萬股的3.00%。
其中,首次授予限制性股票1148.00萬股,約佔公司目前總股本的2.74%,預留107.52萬股,佔該次限制性股票授予總量的8.56%,約佔公司目前總股本的0.26%。
該計劃限制性股票首次授予價格為每股4.30元。
該計劃擬首次授予的激勵對象為147人,包括公司公吿本激勵計劃草案時在公司(含下屬企業)任職的董事、高級管理人員以及中層管理人員。
該激勵計劃的有效期為自限制性股票首次授予之日起至所有限制性股票解鎖或回購註銷完畢之日止,最長不超過72個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.